Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer.
View Article and Find Full Text PDFReactive oxygen species (ROS)-mediated immunogenic cell death (ICD) is crucial in radioimmunotherapy by boosting innate antitumor immunity. However, the hypoxic tumor microenvironment (TME) often impedes ROS production, limiting the efficacy of radiotherapy. To tackle this challenge, a combination therapy involving radiotherapy and immune checkpoint blockade (ICB) with anti-programmed death-ligand 1 (PD-L1) has been explored to enhance antitumor effects and reprogram the immunosuppressive TME.
View Article and Find Full Text PDFWe demonstrate a hybrid nanocomposite combining mesoporous silica, p , as a host medium and guest lithium niobate nanocrystals embedded into tubular silica nanochannels by calcination of the precursor mixed solution of lithium and niobium salts. High-resolution transmission electron microscopy, X-ray diffraction and Raman scattering techniques reveal trigonal nanocrystals within the p nanochannels, indicating their random texture morphology. Annealing at high temperatures ( 950 C) during calcination also leads to partial crystallization of the p matrix with the formation of trigonal - nanocrystals.
View Article and Find Full Text PDF